Bevacizumab (Avastin®), a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its activity, has demonstrated a cytotoxic activity in various cancers, such as colorectal, lung, renal and breast cancer [27]. This evidence concerns the gene VEGFA and breast cancer.